JP2020531481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531481A5 JP2020531481A5 JP2020509482A JP2020509482A JP2020531481A5 JP 2020531481 A5 JP2020531481 A5 JP 2020531481A5 JP 2020509482 A JP2020509482 A JP 2020509482A JP 2020509482 A JP2020509482 A JP 2020509482A JP 2020531481 A5 JP2020531481 A5 JP 2020531481A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 104
- 150000003839 salts Chemical class 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 239000001257 hydrogen Substances 0.000 claims description 33
- 150000002431 hydrogen Chemical class 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical group 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 11
- 229910052805 deuterium Inorganic materials 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 9
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 101000599042 Homo sapiens Zinc finger protein Aiolos Proteins 0.000 claims description 6
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
- 102100037798 Zinc finger protein Aiolos Human genes 0.000 claims description 6
- 102100037796 Zinc finger protein Helios Human genes 0.000 claims description 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 108010013958 Ikaros Transcription Factor Proteins 0.000 claims description 5
- 102000017182 Ikaros Transcription Factor Human genes 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 108090001005 Interleukin-6 Proteins 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 5
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- -1 nitro, amino Chemical group 0.000 claims description 4
- SQQWBSBBCSFQGC-JLHYYAGUSA-N ubiquinone-2 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CCC=C(C)C)=C(C)C1=O SQQWBSBBCSFQGC-JLHYYAGUSA-N 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 201000002661 Spondylitis Diseases 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 125000004405 heteroalkoxy group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 34
- 238000000034 method Methods 0.000 description 32
- 125000000217 alkyl group Chemical group 0.000 description 15
- 125000003545 alkoxy group Chemical group 0.000 description 11
- 125000001188 haloalkyl group Chemical group 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 102100034357 Casein kinase I isoform alpha Human genes 0.000 description 3
- 101000994700 Homo sapiens Casein kinase I isoform alpha Proteins 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000037875 astrocytosis Diseases 0.000 description 2
- 230000007341 astrogliosis Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- QSKAFYPHTWQOHK-GWHBCOKCSA-N CC(C)(C)NS(c1cc(Nc2nc(Nc(cc3)ccc3OCCCOCCNc(ccc3c4CN([C@@H](CCCC(N5)=O)C5=O)C3=O)c4OCc3ccc(CN4CCOCC4)cc3)ncc2C)ccc1)(=O)=O Chemical compound CC(C)(C)NS(c1cc(Nc2nc(Nc(cc3)ccc3OCCCOCCNc(ccc3c4CN([C@@H](CCCC(N5)=O)C5=O)C3=O)c4OCc3ccc(CN4CCOCC4)cc3)ncc2C)ccc1)(=O)=O QSKAFYPHTWQOHK-GWHBCOKCSA-N 0.000 description 1
- AAXJNKVSWJVRIV-QFIPXVFZSA-N CN(C[C@@H](C(N1)=O)N(Cc2c3cccc2OCc2ccc(CN4CCOCC4)cc2)C3=O)CC1=O Chemical compound CN(C[C@@H](C(N1)=O)N(Cc2c3cccc2OCc2ccc(CN4CCOCC4)cc2)C3=O)CC1=O AAXJNKVSWJVRIV-QFIPXVFZSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 0 O=C(*(C1)C(CCCC(N2)=O)C2=O)c2c1c(OCc1ccc(CN3CCOCC3)cc1)ccc2 Chemical compound O=C(*(C1)C(CCCC(N2)=O)C2=O)c2c1c(OCc1ccc(CN3CCOCC3)cc1)ccc2 0.000 description 1
- JYGFCCGLVYYSFL-QFIPXVFZSA-N O=C(c1c(C2)c(OCc3ccc(C4CCNCC4)cc3)ccc1)N2[C@@H](CCCC(N1)=O)C1=O Chemical compound O=C(c1c(C2)c(OCc3ccc(C4CCNCC4)cc3)ccc1)N2[C@@H](CCCC(N1)=O)C1=O JYGFCCGLVYYSFL-QFIPXVFZSA-N 0.000 description 1
- XLPXIPBBRITDKY-QFIPXVFZSA-N O=C(c1c(C2)c(OCc3ccc(CN4CCOCC4)c(Cl)c3)ccc1)N2[C@@H](CCCC(N1)=O)C1=O Chemical compound O=C(c1c(C2)c(OCc3ccc(CN4CCOCC4)c(Cl)c3)ccc1)N2[C@@H](CCCC(N1)=O)C1=O XLPXIPBBRITDKY-QFIPXVFZSA-N 0.000 description 1
- RCNPOXSADORVLD-NRFANRHFSA-N O=C(c1c(C2)c(OCc3ccc(CN4CCOCC4)cc3)ccc1)N2[C@@H](CNCC(N1)=O)C1=O Chemical compound O=C(c1c(C2)c(OCc3ccc(CN4CCOCC4)cc3)ccc1)N2[C@@H](CNCC(N1)=O)C1=O RCNPOXSADORVLD-NRFANRHFSA-N 0.000 description 1
- SKRZNUCTWROARD-NRFANRHFSA-N O=C(c1c(C2)c(OCc3ccc(CN4CCOCC4)cc3)ccc1)N2[C@@H](COCC(N1)=O)C1=O Chemical compound O=C(c1c(C2)c(OCc3ccc(CN4CCOCC4)cc3)ccc1)N2[C@@H](COCC(N1)=O)C1=O SKRZNUCTWROARD-NRFANRHFSA-N 0.000 description 1
- XHZIADWOJXZEME-VWLOTQADSA-N O=C(c1c(C2)c(OCc3ccc(CN4c(cccc5)c5OCC4)cc3)ccc1)N2[C@@H](CCCC(N1)=O)C1=O Chemical compound O=C(c1c(C2)c(OCc3ccc(CN4c(cccc5)c5OCC4)cc3)ccc1)N2[C@@H](CCCC(N1)=O)C1=O XHZIADWOJXZEME-VWLOTQADSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762550489P | 2017-08-25 | 2017-08-25 | |
| US62/550,489 | 2017-08-25 | ||
| PCT/US2018/045626 WO2019040274A1 (en) | 2017-08-25 | 2018-08-07 | ETHER COMPOUNDS AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020531481A JP2020531481A (ja) | 2020-11-05 |
| JP2020531481A5 true JP2020531481A5 (enExample) | 2021-09-16 |
Family
ID=63350615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020509482A Pending JP2020531481A (ja) | 2017-08-25 | 2018-08-07 | エーテル化合物およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10513515B2 (enExample) |
| EP (1) | EP3672955A1 (enExample) |
| JP (1) | JP2020531481A (enExample) |
| CN (1) | CN111247138A (enExample) |
| AU (1) | AU2018321567A1 (enExample) |
| CA (1) | CA3072543A1 (enExample) |
| TW (2) | TWI742303B (enExample) |
| WO (1) | WO2019040274A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4467143B1 (en) | 2017-07-10 | 2026-03-11 | Celgene Corporation | Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile |
| CA3106239A1 (en) | 2018-07-27 | 2020-01-30 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
| US20230093099A1 (en) * | 2019-04-02 | 2023-03-23 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| WO2021222150A2 (en) | 2020-04-28 | 2021-11-04 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| CN113896711A (zh) * | 2020-07-06 | 2022-01-07 | 北京诺诚健华医药科技有限公司 | 杂环类免疫调节剂 |
| WO2022012622A1 (en) * | 2020-07-16 | 2022-01-20 | Beigene, Ltd. | Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use |
| BR112023000817A2 (pt) | 2020-07-20 | 2023-02-07 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Derivado de isoindolina contendo enxofre, e método de preparação do mesmo e uso médico do mesmo |
| US20240025863A1 (en) | 2020-09-16 | 2024-01-25 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022087335A1 (en) | 2020-10-23 | 2022-04-28 | Biotheryx, Inc. | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| CN117203196A (zh) | 2020-12-14 | 2023-12-08 | 拜欧斯瑞克斯公司 | Pde4降解剂、药物组合物和治疗应用 |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| WO2022251588A1 (en) * | 2021-05-27 | 2022-12-01 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| KR20240053589A (ko) * | 2021-07-30 | 2024-04-24 | 하이노바 파마슈티컬스 인코포레이티드 | 이중 기능성 키메라 헤테로 고리 화합물 및 이의 안드로겐 수용체 분해제로서의 용도 |
| WO2023025136A1 (zh) * | 2021-08-27 | 2023-03-02 | 杭州格博生物医药有限公司 | 异吲哚啉酮化合物及其用途 |
| US12419962B2 (en) | 2022-03-16 | 2025-09-23 | Biotheryx, Inc. | Quinazolines, pharmaceutical compositions, and therapeutic applications |
| CN118019736A (zh) * | 2022-09-08 | 2024-05-10 | 标新生物医药科技(上海)有限公司 | 基于cereblon蛋白设计的分子胶化合物及其应用 |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN119684303A (zh) * | 2023-12-28 | 2025-03-25 | 上海超阳药业有限公司 | 一种双功能可降解雄激素受体的杂环化合物及其应用 |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
| DE102024129145A1 (de) | 2024-10-09 | 2026-04-09 | Balluff Gmbh | Sensorelement |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE292451C (enExample) | ||||
| CA793864A (en) | 1968-09-03 | G. Bassiri Taghi | Epsilon-caprolactams | |
| US3331835A (en) | 1965-01-07 | 1967-07-18 | Allied Chem | Novel epsilon-caprolactams |
| BE793517A (fr) | 1972-01-03 | 1973-06-29 | Bayer Ag | Colorants anthraquinoniques |
| US4339600A (en) | 1976-05-10 | 1982-07-13 | E. R. Squibb & Sons, Inc. | Compounds for alleviating angiotensin related hypertension |
| US4415496A (en) | 1981-03-23 | 1983-11-15 | Merck & Co., Inc. | Bicyclic lactams |
| US4644069A (en) | 1984-08-15 | 1987-02-17 | Ciba-Geigy Corporation | Process for the preparation of dimethylmaleic anhydride |
| DE3833892A1 (de) | 1988-10-05 | 1990-04-12 | Bayer Ag | Basische 4-aryl-dhp-amide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| SU1708812A1 (ru) | 1989-10-03 | 1992-01-30 | Отдел Тонкого Органического Синтеза Института Химии Башкирского Научного Центра Уральского Отделения Ан Ссср | @ , @ -Фталимидо- @ -капролактамы как промежуточные продукты дл синтеза N @ -метил- @ -лизина гидрохлорида |
| EP0446899A1 (en) | 1990-03-16 | 1991-09-18 | Konica Corporation | Silver halide photographic material |
| DE4125292A1 (de) | 1991-07-31 | 1993-02-04 | Kali Chemie Pharma Gmbh | 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5272158A (en) | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5504080A (en) | 1992-10-28 | 1996-04-02 | Bristol-Myers Squibb Co. | Benzo-fused lactams |
| DE69329701T2 (de) | 1992-10-30 | 2001-05-10 | Merrell Pharmaceuticals Inc., Cincinnati | Mercaptoacetylamid substituiertes bizyclisches laktam zur verwendung als enkephalinase und ace-hemmer |
| EP0678106A4 (en) | 1993-01-11 | 1995-12-27 | Univ Pennsylvania | POLYCYCLIC AROMATIC COMPOUNDS WITH NON-LINEAR OPTICAL PROPERTIES. |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5631280A (en) | 1995-03-29 | 1997-05-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5932582A (en) | 1996-06-28 | 1999-08-03 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US6429212B1 (en) | 1996-08-16 | 2002-08-06 | Ishihara Sangyo Kaisha Ltd. | Medicinal composition |
| ATE493983T1 (de) | 1996-11-05 | 2011-01-15 | Childrens Medical Center | Thalidomide und dexamethason für die behandlung von tumors |
| US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CA2285264A1 (en) | 1997-04-25 | 1998-11-05 | Michiyo Gyoten | Condensed pyridazine derivatives, their production and use |
| EP0927992A4 (en) | 1997-07-17 | 1999-09-15 | Sony Corp | MAGNETIC RECORDING MEDIUM AND MAGNETIC RECORDING / REPRODUCING DEVICE COMPRISING SAME |
| AU9309898A (en) | 1997-09-09 | 1999-03-29 | Du Pont Pharmaceuticals Company | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa |
| JP2000159761A (ja) | 1998-11-30 | 2000-06-13 | Yoshio Takeuchi | フルオロサリドマイド |
| WO2000034437A2 (en) | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| AU4485400A (en) | 1999-04-26 | 2000-11-10 | Advanced Life Sciences Inc. | Synthetic indolocarbazole regioisomers and uses thereof |
| US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
| ATE277048T1 (de) | 1999-06-15 | 2004-10-15 | Bristol Myers Squibb Pharma Co | Substituierte hetercyclisch kondensierte gamma carboline |
| FR2800739B1 (fr) | 1999-11-04 | 2002-10-11 | Corning Sa | Naphtopyranes avec un heterocycle en position 5,6, preparation et compositions et matrices (co) polymeres les renfermant |
| FR2801054B1 (fr) | 1999-11-17 | 2003-06-13 | Adir | Nouveaux derives de 12,13-(pyranosyl)-indolo[2,3-a]pyrrolo [3,4-c]carbazole et 12,13-(pyranosyl)-furo[3,4-c]indolo [2,3-a]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6388090B2 (en) | 2000-01-14 | 2002-05-14 | Orion Corporation | Imidazole derivatives |
| US6686477B2 (en) | 2000-09-29 | 2004-02-03 | Eastman Chemical Company | Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| AU2002254375A1 (en) | 2001-03-30 | 2002-10-15 | Merck And Co., Inc. | Inhibitors of prenyl-protein transferase |
| US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| DE10137163A1 (de) | 2001-07-30 | 2003-02-13 | Bayer Ag | Substituierte Isoindole und ihre Verwendung |
| WO2003027314A2 (en) | 2001-09-27 | 2003-04-03 | Linden Technologies, Inc. | Protected linker compounds |
| US20040110757A1 (en) | 2002-03-21 | 2004-06-10 | Thomas Arrhenius | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis |
| WO2004080983A1 (en) | 2003-03-14 | 2004-09-23 | Astrazeneca Ab | Novel lactams and uses thereof |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| DE10317817A1 (de) | 2003-04-16 | 2004-11-04 | Chromeon Gmbh | Pyrrolopyrrole als fluoreszente Marker für Biomoleküle und sphärische Partikel |
| AU2004234087A1 (en) | 2003-04-28 | 2004-11-11 | Tibotec Pharmaceuticals Ltd. | HIV integrase inhibitors |
| WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| WO2005121138A2 (en) | 2004-06-03 | 2005-12-22 | Rigel Pharmaceuticals, Inc. | Heterotricyclic compounds for use as hcv inhibitors |
| WO2006034419A2 (en) | 2004-09-21 | 2006-03-30 | Athersys, Inc. | Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof |
| AU2006212765B2 (en) | 2005-02-09 | 2012-02-02 | 3M Innovative Properties Company | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines |
| AR056968A1 (es) | 2005-04-11 | 2007-11-07 | Xenon Pharmaceuticals Inc | Compuestos espiro-oxindol y composiciones farmacéuticas |
| US7592467B2 (en) | 2005-04-11 | 2009-09-22 | Probiodrug Ag | Inhibitors of prolyl endopeptidase |
| TW200728277A (en) | 2005-06-29 | 2007-08-01 | Palau Pharma Sa | Bicyclic derivatives as P38 inhibitors |
| WO2007000337A1 (en) | 2005-06-29 | 2007-01-04 | Palau Pharma, S.A. | Bicyclic derivatives as p38 kinase inhibitors |
| BRPI0613958A2 (pt) | 2005-06-29 | 2011-02-22 | Palau Pharma Sa | composto bicìclico, seu uso como inibidor p38 e composição farmacêutica contendo o mesmo |
| WO2007028789A1 (en) | 2005-09-07 | 2007-03-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Quinazoline derivatives as antiviral agents |
| WO2007126941A2 (en) | 2006-03-24 | 2007-11-08 | Archemix Corp. | Solid support reagents for synthesis |
| US20100297046A1 (en) | 2006-03-31 | 2010-11-25 | Dynamis Therapeutics, Inc. | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors |
| US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| WO2008037266A1 (en) | 2006-09-25 | 2008-04-03 | Universite Libre De Bruxelles | Inhibitors of conventional protein kinase c isozymes and use thereof for treating inflammatory diseases |
| US8143284B2 (en) | 2006-10-05 | 2012-03-27 | Abbott Laboratories | Poly(ADP-ribose)polymerase inhibitors |
| AR063311A1 (es) | 2006-10-18 | 2009-01-21 | Novartis Ag | Compuestos organicos |
| JP2009023986A (ja) | 2006-11-08 | 2009-02-05 | Pharma Ip | 抗癌剤としてのビアリール誘導体 |
| CN101186611B (zh) | 2006-11-15 | 2011-05-18 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用 |
| WO2008073865A2 (en) | 2006-12-11 | 2008-06-19 | Novartis Ag | Method of preventing or treating myocardial ischemia |
| KR20090117730A (ko) | 2007-01-08 | 2009-11-12 | 폴리에라 코퍼레이션 | 아렌-비스(디카르복스이미드)-기재 반도체 물질, 및 이를 제조하기 위한 관련된 중간체의 제조 방법 |
| GB0707051D0 (en) | 2007-04-12 | 2007-05-30 | Istituto Di Ricerche D Biolog | Antiviral agents |
| WO2009039635A1 (en) | 2007-09-24 | 2009-04-02 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| KR101124350B1 (ko) | 2007-10-17 | 2012-03-15 | 한국화학연구원 | 항암 활성을 갖는 페난트렌 락탐 유도체, 이의 제조방법 및이를 포함하는 약학 조성물 |
| WO2009070533A1 (en) | 2007-11-29 | 2009-06-04 | Complegen, Inc. | Methods of inhibiting steroyl coa desaturase |
| JP5632612B2 (ja) | 2007-12-05 | 2014-11-26 | あすか製薬株式会社 | ラクタム化合物又はその塩及びｐｐａｒ活性化剤 |
| EP2072506A1 (de) | 2007-12-21 | 2009-06-24 | Bayer CropScience AG | Thiazolyloxyphenylamidine oder Thiadiazolyloxyphenylamidine und deren Verwendung als Fungizide |
| RU2544856C2 (ru) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US9446995B2 (en) | 2012-05-21 | 2016-09-20 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
| WO2009112445A1 (en) | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
| MX2010010272A (es) | 2008-03-19 | 2011-05-25 | Chembridge Corp | Nuevos inhibidores de tirosina quinasa. |
| WO2009156098A2 (de) | 2008-06-27 | 2009-12-30 | Bayer Cropscience Ag | Thiadiazolyloxyphenylamidine und deren verwendung als fungizide |
| WO2010011924A2 (en) | 2008-07-24 | 2010-01-28 | Draths Corporation | Monomers derived from alpha-or beta-amino-e-caprolactam and polymers made therefrom |
| EP2373645A4 (en) | 2008-12-08 | 2012-05-02 | Sirtris Pharmaceuticals Inc | ISOINDOLINONE AND RELATED ANALOGUES AS SIRTUIN MODULATORS |
| CA2774871C (en) | 2009-10-20 | 2018-05-29 | Tokyo Institute Of Technology | Screening method utilizing thalidomide-targeting factor |
| JP5734570B2 (ja) | 2010-01-28 | 2015-06-17 | 富士フイルム株式会社 | 顔料微粒子の製造方法 |
| PL3202460T3 (pl) * | 2010-02-11 | 2019-12-31 | Celgene Corporation | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| KR20110119282A (ko) | 2010-04-27 | 2011-11-02 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 전자재료용 화합물 및 이를 채용하고 있는 유기 전계 발광 소자 |
| US8697690B2 (en) | 2010-07-01 | 2014-04-15 | Merck Sharp & Dohme Corp. | Isoindolone M1 receptor positive allosteric modulators |
| WO2012037155A2 (en) | 2010-09-13 | 2012-03-22 | Gtx, Inc. | Tyrosine kinase inhibitors |
| US8742097B2 (en) | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| TWI445696B (zh) | 2010-11-29 | 2014-07-21 | Univ Nat Yang Ming | 標靶人類胸線核苷酸激酶誘導惡性腫瘤中的ｄｎａ修復毒性 |
| JP5728921B2 (ja) | 2010-12-10 | 2015-06-03 | コニカミノルタ株式会社 | 光学フィルム、及びそれを用いた偏光板、液晶表示装置 |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| WO2012158475A1 (en) | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-linked lactam m1 receptor positive allosteric modulators |
| SG194770A1 (en) | 2011-05-27 | 2013-12-30 | Probiodrug Ag | Radiolabelled glutaminyl cyclase inhibitors |
| WO2013010218A1 (en) | 2011-07-15 | 2013-01-24 | Freie Universität Berlin | Inhibition of clathrin |
| WO2013106409A1 (en) | 2012-01-10 | 2013-07-18 | Merck Patent Gmbh | Benzamide derivatives as modulators of the follicle stimulating hormone |
| KR20130131663A (ko) | 2012-05-24 | 2013-12-04 | 코오롱생명과학 주식회사 | 벤질리딘 프탈이미드 단량체, 이의 제조 방법, 이를 포함하는 중합체, 이를 포함하는 광배향막 및 이를 포함하는 위상차 필름 |
| KR101592628B1 (ko) | 2012-09-20 | 2016-02-11 | 주식회사 엘지화학 | 이미다졸 유도체 및 이를 이용한 유기 전자 소자 |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US20150272939A1 (en) | 2012-10-02 | 2015-10-01 | Yale University | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase |
| BR112015015584A2 (pt) | 2012-12-27 | 2017-12-12 | Baruch S Blumberg Inst | novos agentes antivirais contra infecção por hbv |
| US20140213538A1 (en) | 2013-01-15 | 2014-07-31 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| WO2014116573A1 (en) * | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| KR20140103447A (ko) | 2013-02-18 | 2014-08-27 | 코오롱생명과학 주식회사 | 벤질리딘 프탈이미드 단량체, 이의 제조 방법, 이를 포함하는 중합체, 이를 포함하는 광배향막 및 이를 포함하는 위상차 필름 |
| CN104004122B (zh) | 2014-05-08 | 2016-05-11 | 中国科学院长春应用化学研究所 | 新型温敏性聚合物及用可再生资源l-赖氨酸制备新型温敏性聚合物的方法 |
| NZ731789A (en) * | 2014-10-30 | 2019-04-26 | Kangpu Biopharmaceuticals Ltd | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
| SG11201708303XA (en) | 2015-05-22 | 2017-11-29 | Biotheryx Inc | Compounds targeting proteins, compositions, methods, and uses thereof |
| WO2017024318A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| CA3018429A1 (en) | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use |
| WO2017201069A1 (en) * | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
| US10406165B2 (en) * | 2017-03-14 | 2019-09-10 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| US11584734B2 (en) * | 2017-08-15 | 2023-02-21 | Global Blood Therapeutics, Inc. | Tricyclic compounds as histone methyltransferase inhibitors |
| WO2019241271A1 (en) * | 2018-06-13 | 2019-12-19 | Biotheryx, Inc. | Fused thiophene compounds |
| JP2022533260A (ja) * | 2019-05-24 | 2022-07-21 | バイオセリックス， インコーポレイテッド | タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用 |
-
2018
- 2018-08-06 US US16/056,163 patent/US10513515B2/en active Active
- 2018-08-07 AU AU2018321567A patent/AU2018321567A1/en not_active Abandoned
- 2018-08-07 JP JP2020509482A patent/JP2020531481A/ja active Pending
- 2018-08-07 CN CN201880067990.7A patent/CN111247138A/zh active Pending
- 2018-08-07 CA CA3072543A patent/CA3072543A1/en active Pending
- 2018-08-07 EP EP18759219.1A patent/EP3672955A1/en not_active Withdrawn
- 2018-08-07 WO PCT/US2018/045626 patent/WO2019040274A1/en not_active Ceased
- 2018-08-21 TW TW107129086A patent/TWI742303B/zh not_active IP Right Cessation
- 2018-08-21 TW TW110132428A patent/TW202222794A/zh unknown
-
2019
- 2019-12-18 US US16/719,805 patent/US10927104B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531481A5 (enExample) | ||
| JP2021510376A5 (enExample) | ||
| Wang et al. | STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor | |
| JP2019527202A5 (enExample) | ||
| Zhao et al. | Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma | |
| JP2017538677A5 (enExample) | ||
| US10772894B2 (en) | Compositions and therapeutic methods for the treatment of complement-associated diseases | |
| Kim et al. | Prognostic significance of initial platelet counts and fibrinogen level in advanced non-small cell lung cancer | |
| JP2021523112A5 (enExample) | ||
| JP2019529444A5 (enExample) | ||
| JP2020536888A5 (enExample) | ||
| JP2021522166A5 (enExample) | ||
| JP2018532690A5 (enExample) | ||
| AU4112500A (en) | Phthalazine derivatives for treating inflammatory diseases | |
| Ma et al. | Bazedoxifene exhibits growth suppressive activity by targeting interleukin‐6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma | |
| US20190055235A1 (en) | Substituted bicyclic compounds as bromodomain inhibitors | |
| JP2015506985A5 (enExample) | ||
| KR20140035334A (ko) | 종양 치료제 | |
| JP2021514395A5 (enExample) | ||
| Matsuda et al. | A comparative safety profile assessment of oncolytic virus therapy based on clinical trials | |
| CN114364679A (zh) | 作为Syk和VEGFR2双靶点抑制剂的1H-吡唑衍生物及应用 | |
| JP2024511389A5 (enExample) | ||
| JP2019535709A5 (enExample) | ||
| RU2017105827A (ru) | Сочетанная терапия | |
| de Waard et al. | Expression of multidrug resistance transporter ABCB5 in a murine model of human conjunctival melanoma |